Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

27.11 -0.24 (-0.86%)
Streaming Delayed Price Updated: 10:22 AM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
From Roivant Sciences
Via GlobeNewswire
News headline image
6 Analysts Assess Roivant Sciences: What You Need To Know ↗
 
Via Benzinga
News headline image
Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17 ↗
Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study,... 
Via Stocktwits
News headline image
Why Roivant Sciences Stock Is Soaring Today ↗
The drugmaker just cleared a major hurdle to winning FDA approval for a promising autoimmune disease drug. 
Via The Motley Fool
News headline image
A Glimpse of Roivant Sciences's Earnings Potential ↗
 
Via Benzinga
News headline image
What Does the Market Think About Roivant Sciences? ↗
 
Via Benzinga
News headline image
Peering Into Roivant Sciences's Recent Short Interest ↗
 
Via Benzinga
News headline image
Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial ↗
Brepocitinib showed significant improvements in skin and muscle symptoms in dermatomyositis, with reduced steroid use and consistent safety results. 
Via Benzinga
News headline image
Wednesday's session: gap up and gap down stocks ↗
Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
News headline image
Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Roivant Leaps Into A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease ↗
The company is working on a treatment for an autoimmune disease that affects the skin and muscles. 
Via Investor's Business Daily
News headline image
Roivant Sciences's Earnings Outlook ↗
 
Via Benzinga
News headline image
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
From Roivant Sciences
Via GlobeNewswire
News headline image
Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
From Pulmovant, Inc.
Via GlobeNewswire
News headline image
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
From Roivant Sciences
Via GlobeNewswire
News headline image
Why Roivant Sciences Stock Bounced Back on Tuesday ↗
Investors were in a forgiving mood after Monday's dispiriting earnings release. 
Via The Motley Fool
News headline image
Why Roivant Sciences Stock Was Slipping on Monday ↗
The distinctive biotech wasn't a sector favorite as the trading week began. 
Via The Motley Fool
News headline image
Beyond the Headlines: A Look at Today's Key Corporate Earnings Reports
Today, August 11, 2025, marks a significant day for investors looking beyond the typical S&P 500 giants, as a diverse array of companies across various sectors unveiled their latest quarterly earnings.... 
Via MarketMinute
Topics Economy Stocks
News headline image
Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025
From Roivant Sciences
Via GlobeNewswire
News headline image
Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics
From Pulmovant, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 11, 2025 ↗
 
Via Benzinga
News headline image
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
From Roivant Sciences
Via GlobeNewswire
News headline image
Stocks Edge Higher After Court Stifles Trump Tariffs, Nvidia Rallies To 3-Month Highs, Bitcoin Dips Below $107K: What's Driving Markets Thursday? ↗
Wall Street hovered slightly higher by midday Thursday, giving up a chunk of strong overnight gains in futures markets that were triggered by a federal court ruling suspending a large portion of... 
Via Benzinga
Topics Government
News headline image
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
News headline image
Earnings Scheduled For May 29, 2025 ↗
 
Via Benzinga
News headline image
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025
From Roivant Sciences
Via GlobeNewswire
News headline image
Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift ↗
The company is getting a new chief executive and a new chief financial officer amid sweeping changes. 
Via Investor's Business Daily
Topics Government
News headline image
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
From Roivant Sciences
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.